We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chipotle (CMG) to Report Q4 Earnings: What's in the Cards?
Read MoreHide Full Article
Chipotle Mexican Grill, Inc. (CMG - Free Report) is scheduled to report fourth-quarter 2019 results on Feb 4, after market close. In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate by 19.4%.
Q4 Expectations
The Zacks Consensus Estimate for fourth-quarter earnings is pegged at $2.75, higher than the year-ago reported figure of $1.72. Over the past seven days, the company’s earnings estimates have witnessed an upward trend by 0.7%. For quarterly revenues, the consensus mark stands at $1,401 million, suggesting growth of 14.2% from prior-year quarter.
Let’s check out how things have shaped up for the announcement.
Factors at Play
New menu innovation, continued use of technology and higher store opening are expected to have contributed to Chipotle’s comps growth in the fourth quarter. The company has been shifting its strategy from giveaways, discounts and rewards to new menu items, operational excellence, enhancement of guest experience, technology-driven convenience, and more aggressive brand marketing. These sales-building efforts are likely to have aided the company’s top line in the quarter to be reported.
However, wage inflation and higher marketing and delivery expenses are expected to have hurt margins in the to-be-reported quarter.
Our proven model predicts an earnings beat for Chipotle this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Chipotle has an Earnings ESP of +3.25% and a Zacks Rank #2.
Other Stocks Poised to Beat Earnings Estimates
Here are some other stocks from the Zacks Retail-Wholesale space that investors may consider as our model shows that these too have the right combination of elements to post an earnings beat this quarter:
Jack in The Box Inc. (JACK - Free Report) carries a Zacks rank #2 and has an Earnings ESP of +4.92%.
Rite Aid Corporation sports a Zacks Rank #1 and has an Earnings ESP of +52.63%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Chipotle (CMG) to Report Q4 Earnings: What's in the Cards?
Chipotle Mexican Grill, Inc. (CMG - Free Report) is scheduled to report fourth-quarter 2019 results on Feb 4, after market close. In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate by 19.4%.
Q4 Expectations
The Zacks Consensus Estimate for fourth-quarter earnings is pegged at $2.75, higher than the year-ago reported figure of $1.72. Over the past seven days, the company’s earnings estimates have witnessed an upward trend by 0.7%. For quarterly revenues, the consensus mark stands at $1,401 million, suggesting growth of 14.2% from prior-year quarter.
Let’s check out how things have shaped up for the announcement.
Factors at Play
New menu innovation, continued use of technology and higher store opening are expected to have contributed to Chipotle’s comps growth in the fourth quarter. The company has been shifting its strategy from giveaways, discounts and rewards to new menu items, operational excellence, enhancement of guest experience, technology-driven convenience, and more aggressive brand marketing. These sales-building efforts are likely to have aided the company’s top line in the quarter to be reported.
However, wage inflation and higher marketing and delivery expenses are expected to have hurt margins in the to-be-reported quarter.
Chipotle Mexican Grill, Inc. Price and Consensus
Chipotle Mexican Grill, Inc. price-consensus-chart | Chipotle Mexican Grill, Inc. Quote
What Our Model Says
Our proven model predicts an earnings beat for Chipotle this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Chipotle has an Earnings ESP of +3.25% and a Zacks Rank #2.
Other Stocks Poised to Beat Earnings Estimates
Here are some other stocks from the Zacks Retail-Wholesale space that investors may consider as our model shows that these too have the right combination of elements to post an earnings beat this quarter:
Denny's Corporation (DENN - Free Report) currently sports a Zacks Rank #1 and has an Earnings ESP of +5.00%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Jack in The Box Inc. (JACK - Free Report) carries a Zacks rank #2 and has an Earnings ESP of +4.92%.
Rite Aid Corporation sports a Zacks Rank #1 and has an Earnings ESP of +52.63%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>